Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
Clinical Trials
9
3 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
2
22.2%
Completed
2
22.2%
Enrolling By Invitation
1
11.1%
Recruiting
2
22.2%
Terminated
2
22.2%
No approval data available
- Cellectis' board approved a strategic transformation on September 11, 2026, ending internal development of CAR-T candidates lasme-cel and eti-cel and refocusing on in vivo gene editing. - The company will advance two preclinical programs, .HEAL-101 targeting APOC3 for severe hypertriglyceridemia and .HEAL-201 targeting PCSK9 for severe hypercholesterolemia, both LNP-delivered. - Cellectis attributed the CAR-T exit to improved frontline regimens, bispecific antibody competition and slower enrollment, and will seek partners for the discontinued assets. - The operational realignment is designed to extend the cash runway into H2 2028, with preliminary Phase 1 data from .HEAL-101 expected in H2 2027 and .HEAL-201 in H1 2028.
- Shennon Biotechnologies raised $12 million in new financing, bringing total capital raised to $25 million since its founding in 2021. - The company appointed industry veteran Cyril Konto, M.D., as CEO, with founder Li Sun, Ph.D., moving to President and Chief Technology Officer. - ShennonBio disclosed three T-cell engager programs: SBT-121 for small cell lung cancer, SBT-201 for ovarian cancer and SBT-425 for hepatocellular carcinoma. - The financing supports advancement of the company's integrated discovery platform and its first T-cell engager candidates toward an IND filing and Phase 1 development.
- A new market report forecasts continued expansion of the global CD70-targeting therapies pipeline across the United States, China, and Europe as candidates advance through clinical trials and regulatory review. - Clinical development increasingly incorporates combination regimens pairing CD70 therapies with immunotherapies, epigenetic inhibitors, chemotherapy, and targeted agents to strengthen responses and address resistance. - Leading companies including Allogene Therapeutics, Ambrx (Johnson & Johnson), Molecular Partners, and CRISPR Therapeutics are advancing differentiated programs through proprietary platforms such as allogeneic cell therapy and DARPin engineering. - The report highlights biomarker-driven development and patient-selection strategies as key levers for more precise clinical positioning across leukemia, lymphoma, renal cell carcinoma, and autoimmune indications.
- The Phase I TRAVERSE trial of ALLO-316, an off-the-shelf CD70-targeted CAR T-cell therapy, achieved a 31.3% objective response rate in heavily pretreated advanced ccRCC patients with high CD70 expression. - Half of patients in the Phase 1b cohort experienced disease control, with some responses lasting over a year after a single infusion and one patient later achieving a complete response. - The study provides the first clinical proof-of-concept that allogeneic CAR T-cell therapy can be active in solid tumors, with a manageable safety profile and no severe neurotoxicity or graft-versus-host disease observed. - Median overall survival was 15.2 months in the Phase 1b cohort and was not reached in patients with high CD70 expression, suggesting CD70 levels may serve as a predictive biomarker.
- Allogene Therapeutics has reported new study results that strengthen the company's development of an off-the-shelf CAR-T therapy for B-cell lymphoma treatment. - The data represents a significant advancement in allogeneic CAR-T cell therapy, offering potential advantages over traditional autologous approaches for blood cancer patients. - Chief Medical Officer Zach Roberts discussed the promising results, which could transform treatment accessibility for B-cell lymphoma patients. - The development addresses ongoing challenges in CAR-T therapy manufacturing and patient access in hematologic malignancies.
- NexImmune's lead candidate NEX-ILE12, a novel interleukin-12 immunomodulator, has shown promising safety profiles and immune activation signals in Phase 1 trials for solid tumors. - The company reported dose-escalation progress without dose-limiting toxicities and plans to initiate combination studies with PD-1 inhibitors by mid-2026. - NexImmune's proprietary Artificial Immune Modulation (AIM) technology differentiates the company by mimicking natural immune synapses, potentially improving efficacy over existing CAR-T approaches. - The company maintains a cash position supporting operations into 2027, though high R&D expenses and potential dilution from future raises remain concerns for investors.
- Arbitration tribunal ruled in favor of Servier, reaffirming Allogene's full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the US, EU, and UK markets. - The decision rejected Cellectis's breach allegations and financial claims, with milestone payments only due upon FDA acceptance of a Biologics License Application. - Allogene approaches a critical 1H 2026 interim futility analysis for its pivotal Phase 2 ALPHA3 trial testing cema-cel in first-line large B-cell lymphoma consolidation.
- Allogene Therapeutics narrowed its GAAP net loss to $0.23 per share in Q2 2025, beating estimates of $0.27 per share while maintaining a strong cash position of $302.6 million. - The company delayed key clinical trial timelines for its lymphoma and autoimmune disease programs by approximately two quarters due to operational challenges at trial sites. - Over 250 patients have been consented for screening across trials, with the ALPHA3 futility analysis for cema-cel now expected in the first half of 2026. - The company's cash runway is projected to extend into the second half of 2027, supporting continued development of its off-the-shelf CAR-T therapy pipeline.
- Allogene Therapeutics has discontinued the FC plus ALLO-647 lymphodepletion arm in its ALPHA3 trial after a patient death from hepatic failure attributed to disseminated adenovirus infection. - The company will proceed with standard fludarabine and cyclophosphamide (FC) lymphodepletion for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma. - This strategic shift eliminates ALLO-647 from all current trials and accelerates focus on the company's next-generation Dagger Platform Technology for future CAR-T development. - The modified ALPHA3 trial continues as a two-arm randomized study comparing cema-cel after standard FC to observation, with futility analysis scheduled for first half 2026.
• The FDA has removed a clinical hold on all five of Allogene Therapeutics' AlloCAR T studies that was imposed in October 2021 following a chromosomal abnormality in a single patient. • A three-month investigation concluded that the chromosomal abnormality was unrelated to Allogene's manufacturing process and had no clinical significance for the patient. • The pivotal phase II trial of ALLO-501A in relapsed/refractory large B-cell lymphoma is scheduled to commence in mid-2022. • Allogene's stock rose over 4% in premarket trading following the announcement of the clinical hold removal.
